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Myostatin, a TGF-b superfamily member, is a negative regulator of muscle
growth. Here we describe how myostatin activity is regulated by syndecan-4,
a ubiquitous transmembrane heparan sulfate proteoglycan. During muscle
regeneration the levels of both syndecan-4 and promyostatin decline gradually
after a sharp increase, concurrently with the release of mature myostatin.
Promyostatin and syndecan-4 co-immunoprecipitate, and the interaction is
heparinase-sensitive. ShRNA-mediated silencing of syndecan-4 reduces
C2C12 myoblast proliferation via blocking the progression from G1- to
S-phase of the cell cycle, which is accompanied by elevated levels of myo-
statin and p21(Waf1/Cip1), and decreases in cyclin E and cyclin D1 expres-
sion. Our results suggest that syndecan-4 functions as a reservoir for
promyostatin regulating the local bioavailability of mature myostatin.
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Skeletal muscle is constantly renewed in response to
injury, exercise, or muscle diseases. A population of
resident stem cells (satellite cells) accounts for skeletal
muscle plasticity, maintenance and regeneration [1–3].
The muscle progenitor satellite cells are mitotically
and physiologically quiescent in healthy muscle; they
are stimulated by local damage to proliferate exten-
sively and form myoblasts that will subsequently dif-
ferentiate and fuse to form muscle fibres. By
understanding the process of skeletal muscle regenera-
tion we might have the possibility to improve it fol-
lowing sport injuries or during aging. Several studies
described that proteoglycans and other components of
the extracellular matrix are involved in tissue regenera-
tion and skeletal muscle differentiation [4–6]. The cru-
cial roles of syndecan (SDC) proteoglycans have been
shown in the regeneration of the skin, vasculature and
skeletal muscle [6].
Syndecans (SDCs) constitute a family of four trans-
membrane heparan sulfate proteoglycans in mammals
[7–9]. They are composed of three distinct domains, an
N-terminal variable extracellular domain with gly-
cosaminoglycan attachment sites, a single conserved
transmembrane domain and a short C-terminal cyto-
plasmic domain with two conserved regions flanking a
variable region unique for each SDC. The extracellular
domains are variable between the SDC family mem-
bers, whereas the transmembrane and cytoplasmic
domains are highly conserved. SDC1 is mainly
expressed in epithelial and plasma cells, SDC2 is
mostly found in mesenchymal cells (fibroblasts and
smooth muscle) and SDC3 is abundant in neural
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tissues and developing musculoskeletal tissues. In
contrast to other SDCs, SDC4 is expressed ubiqui-
tously [7]. Among the different glycosaminoglycan
(GAG) chains, which are attached to the protein core
of SDCs, both heparan sulfate and chondroitin sulfate
chains are represented in SDC1 and SDC3, but only
heparan sulfates are attached to the SDC2 and SDC4
ectodomains.
Heparan sulfates on proteoglycans can either nega-
tively or positively regulate growth factor function by
participating as co-receptors, reservoirs for storage or
transporters [10]. Cell surface heparan sulfate proteo-
glycans can recruit soluble ligands, thereby increasing
their local concentration, and they can also modulate
ligand receptor encounters [7,11], or can protect the
growth factors from proteolytic inactivation [12]. The
ectodomains of SDCs mediate several cell–cell and cell–
matrix interactions via the GAG chains. The extracellu-
lar domains interact with matrix proteins and numerous
growth factors; therefore, SDCs are usually considered
as co-receptors of the primary signalling receptors. Inter-
actions of HER2 (human epidermal growth factor
receptor 2) and EGFR (epithelial growth factor recep-
tor) with SDC1 and SDC4 respectively, have been
reported [13], and SDC1 was identified as a co-receptor
for HGF (hepatocyte growth factor) [14]. Signalling by
FGF (fibroblast growth factor) family members and
HGF is regulated by heparan sulfates [15,16], and both
HGF and the members of the FGF family have been
implicated in satellite cell activation and skeletal muscle
differentiation [10].
One of the cell surface markers of quiescent and pro-
liferating muscle progenitor satellite cells is SDC4 [17].
It was reported that SDC4/ mice are unable to
regenerate damaged muscle and explanted satellite cells
were deficient in activation, proliferation and MyoD
expression [18]. The ubiquitously expressed SDC4 has
an important role in outside-in and inside-out signalling
events in different cell types by, for example influencing
cell-matrix adhesion, endocytosis, exosome biogenesis,
cytokinesis and regulating the activity of Rac1 GTPase
and the level of intracellular calcium [7–9,19].
Myostatin, also known as growth- and differentia-
tion factor 8 (GDF8), belongs to the TGF-beta (trans-
forming growth factor beta) superfamily. It is
synthesized as a precursor protein, promyostatin,
which is cleaved into N-terminal propeptide and C-
terminal active myostatin fragments by the furin fam-
ily of proprotein convertases [20,21]. This cleavage can
occur in the Golgi network or in the extracellular
matrix. Anderson and colleagues identified an extracel-
lular promyostatin pool, which can be activated by
furin, thus localizing myostatin activity through
extracellular localization of promyostatin maturation
[22]. The propeptides can still associate with myostatin
dimer via noncovalent bonds to form an inactive latent
complex which sequesters functional myostatin by pre-
venting its binding to the receptor [21]. The members
of the bone morphogenetic protein-1/tolloid (BMP-1/
TLD) family of metalloproteinases are involved in
activating this latent myostatin in vivo [23]. The
mature myostatin dimer acts through activin type II
receptor ActRIIB and to a lesser extent ActRIIA [21].
The signalling involves the phosphorylation of Smad2/
3 transcription factors [24,25], and the inhibition of
the PI3K/Akt pathway [26,27]. Myostatin was shown
to up-regulate the expression of p21(Waf1/Cip1), thus
preventing the progression of myoblasts from the
G1- to S-phase of the cell cycle [28]. It also inhibits
myoblast differentiation by down-regulating the syn-
thesis and activity of the muscle regulatory factor
MyoD [24].
SDC4 has an essential role in skeletal muscle devel-
opment and regeneration [18]; however, its specific role
in mammalian myoblast (activated satellite cell) prolif-
eration has not been studied yet. In the present study
we found that SDC4 regulates the proliferation of
myoblasts, and silencing of SDC4 decreases the pro-
gression of the cell cycle from G1- to S-phase. Fur-
thermore, we have shown that SDC4 interacts with
promyostatin in a heparan sulfate-dependent manner
and influences the level of mature myostatin. Our
results suggest that SDC4 may regulate the local
bioavailability of mature myostatin by serving as a
reservoir for promyostatin and subsequently inhibiting
the formation of active myostatin.
Materials and methods
Animal model
For the regeneration model of skeletal muscle, the necrosis of
soleus muscle (m. soleus) of male Wistar rats (300–320 g) was
induced by the snake venom notexin (from Notechis scutatus
scutatus; Sigma-Aldrich, St. Louis, MO, USA) under chloral
hydrate anaesthesia as described previously [29]. Briefly,
20 lg notexin in 200 lL of 0.9% NaCl solution was injected
along the whole length of the muscle. The muscles were
removed under anaesthesia on days 0, 1, 3, 4, 5, 7, 10 and 14
after injury (n = 4 in each group). All animal experiments
were conducted under the approval of the Animal Health
Care and Control Institute, Csongrad County, Hungary.
Cell culture and plasmids
C2C12 mouse myoblast cells (ATCC, Manassas, VA, USA)
were cultured in Dulbecco’s modified Eagle’s medium
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(4.5 gL1 glucose with glutamine; Lonza, Basel, Switzer-
land) containing 50 lgmL1 gentamycin (Lonza) and sup-
plemented with 20% fetal bovine serum (Gibco, Thermo
Fisher Scientific, Waltham, MA, USA). Differentiation was
induced by shifting the confluent cultures to medium con-
taining 2% horse serum (Sigma-Aldrich). For SDC4 silenc-
ing the C2C12 cells were stably transfected with plasmids
expressing short hairpin RNAs (shRNA) targeting mouse
SDC4 (shSDC4#1 and shSDC#2), a scrambled target
sequence, or the empty pRS vector using X-tremeGENE
transfection reagent (Roche, Basel, Switzerland). The trans-
fected populations were selected in medium supplemented
with 4 lgmL1 puromycin (Sigma-Aldrich). The plasmids
were obtained from OriGene (TR513122; Rockville, MD,
USA) and targeted the sequences 50-GAA CTG GAA
GAG AAT GAG GTC ATT CCT AA-30 (shSDC4#1), 50-
GCG GCG TGG TAG GCA TCC TCT TTG CCG TT-30
(shSDC4#2) and 50-GCA CTA CCA GAG CTA ACT
CAG ATA GTA CT-30 (scrambled).
Staining, microscopy
Frozen sections (10 lm) of control and regenerating soleus
muscles were fixed in acetone for 5 min and were stained
by haematoxylin (0.1%) and eosin (1%). Photos were taken
with 209 objective using a Nikon Labophot-2 microscope
equipped with Olympus DP71 camera. Cell cultures were
analysed with a Leica DMi1 inverted microscope.
Protein isolation and western blotting
Rat soleus muscles were homogenized in 50 mM Tris-HCl
pH 7.6, 100 mM NaCl, 10 mM EDTA buffer containing
1 mM Na-fluoride, 1 mM Na3VO4 and protease inhibitor
cocktail (Sigma-Aldrich). C2C12 cells were harvested in
RIPA buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxy-
cholate, 2.5 mM sodium pyrophosphate, 1 mM b-
glycerophosphate, 1 mM Na3VO4, 1 lgmL1 leupeptin; Cell
Signaling Technology, Danvers, MA, USA; #9806) supple-
mented with 1 mM Na-fluoride, and protease inhibitor cock-
tail (Sigma-Aldrich). After centrifugation of the samples at
160 000 g for 5 min at 4 °C to eliminate cellular debris the
supernatants were separated by SDS/PAGE, blotted to
nitrocellulose or poly(vinylidene difluoride) membrane. After
blocking, membranes were incubated with antibodies includ-
ing goat anti-SDC4 (sc-9499; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit anti-SDC4 (36-3100; Zymed/
Thermo Fisher Scientific), rabbit anti-myostatin (AB3239;
Chemicon/Merck, Kenilworth, NJ, USA or AB3239-I;
Merck Millipore; Billerica, MA, USA), both recognizing the
C-terminal part of the protein, anti-phospho-Smad2Ser465/467
(44-244G; Invitrogen, Carlsbad, CA, USA), mouse anti-
GAPDH (#2118; Cell Signaling Technology), rabbit anti-
myoD (sc-304), mouse anti-p21 (sc-6246), mouse anti-cyclin
D1 (sc-6281) and rabbit anti-cyclin E (sc-481; all from Santa
Cruz Biotechnology) primary antibodies, followed by incu-
bation with the appropriate horse-radish peroxidase-conju-
gated anti-IgG secondary antibodies [anti-mouse (P0161),
anti-rabbit (P0448), anti-goat (P0160)] from DAKO
(Glostrup, Denmark). Peroxidase activity was visualized
by the ECL procedure (Advansta, Menlo Park, CA,
USA). Quantification of signal intensity was performed by
QUANTITY ONE software (Bio-Rad, Hercules, CA, USA).
Co-immunoprecipitation and heparinase
digestion
Homogenates were pre-cleared with Protein A/G beads in an
effort to reduce the possibility of nonspecific binding of proteins
to the beads. Afterwards the supernatants were incubated over-
night with the antibody of interest followed by incubation with
immobilized Protein A/G (Pierce, Rockford, IL, USA) for 2 h.
Protein A/G slurry was collected by pulse centrifugation, fol-
lowed by washing three times with immunoprecipitation buffer
(25 mM Tris, 150 mM NaCl, pH 7.2). The immunocomplex was
eluted with 0.2 M glycin (pH 2.5). The eluted immunocomplex
was subjected to SDS/PAGE, followed by immunoblotting with
the appropriate antibodies.
To test the role of heparan sulfate chains, the samples were
incubated with anti-SDC4 antibody overnight. After incubation
with Protein A/G, the protein A/G slurry was washed two times
with immunoprecipitation buffer and oncewith heparinase buffer
(50 mM HEPES pH 6.5, 50 mM NaOAc, 150 mM NaCl, 5 mM
CaCl2). The immunoprecipitate was resuspended in heparinase
buffer and digested with 0.4 mU heparinase II enzyme (Sigma-
Aldrich) for 3 h at 37 °C. After digestion both the supernatant
and the eluted immunocomplex were subjected to SDS/PAGE.
QRT-PCR analysis
For qRT-PCR, total RNA was isolated from C2C12 cell lines
and reverse transcribed (three samples for each cell line). TaqMan
probe sets [SDC1: Mm01275869_m1, SDC2: Mm04207492_m1,
SDC3: Mm01179833_m1, SDC4: Mm00488527_m1, glypican-1
(Gpc1): Mm01290371_m1, perlecan (Hspg2): Mm01181173_g1,
myostatin: Mm00440328_m1, HPRT (hypoxanthine-guanine
phosphoribosyltransferase): Mm03024075_m1; all from Thermo-
Fisher Scientific] and the TaqManMasterMix (Roche) were used
with the following program: 10 min at 95 °C, 45 cycles of 95 °C
for 15 s and 60 °C for 1 min. Individual threshold cycle (Ct) val-
ues were normalized to the Ct values of HPRT. Relative gene
expression levels are presented as log2 ratios.
Cell proliferation assay
Equal number of cells of the nontransfected and transfected
cell lines were plated and grown in proliferation media. Cell-
Titer-Glo assays (Promega, Madison, WI, USA) were per-
formed according to the manufacturer’s instructions at 12,
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24 and 36 h after seeding. The luminescence was measured
on FLUOstar Optima plate reader (BMG Labtech, Orten-
berg, Germany).
Cell cycle analysis
The collected cells were washed once with PBS, resuspended
in PBS, and fixed by addition of ice-cold 96% ethanol to
70% final concentration. The fixed cells were pelleted by
centrifugation (at 350 g, 5 min, 4 °C), then resuspended in
PBS containing 50 lgmL1 RNaseA (#EN0531; Thermo
Fisher Scientific). After 30 min incubation at 37 °C propid-
ium iodide (Sigma-Aldrich) was added to 1 lgmL1 final
concentration. Flow cytometry was performed with a Par-
tec FlowMax 3.0 flow cytometer (Sysmex Partec GmbH,
G€orlitz, Germany), and the data were analysed using
FLOWJO software (FlowJo LLC, Ashland, OR, USA).
Statistical analysis
Statistical evaluations were performed by one-way ANOVA
and Newman–Keuls post-test (GraphPad Software Inc., La
Jolla, CA, USA). All data are presented as means  SEM.
Results
The expression of syndecan-4 and myostatin
during in vivo and in vitro myoblast
differentiation
Muscle regeneration can be artificially induced by
injecting the snake venom notexin. It rapidly induces
myonecrosis and, because it does not affect the muscle
progenitor satellite cells, a subsequent regeneration of
the tissue [30]. To monitor the process of regeneration
the cryo-sections of regenerating m. soleus of the rat
were stained with haematoxylin and eosin (Fig. 1). In
the first 3 days abundant inflammatory cells and pro-
liferating myoblasts were observed between the necro-
tic fibres. By days 4–5 regenerating small calibre
myofibres appeared with centrally located nuclei, on
day 7 most of the myofibres had the nuclei in central
position, but their diameters were highly heteroge-
neous. By day 14 the muscle restored its normal mor-
phology with a persistence of central nuclei and a
slightly increased interstitial space (Fig. 1A).
To examine the expression of proteins during regen-
eration we analysed the homogenates of soleus muscle
on different days after notexin injection (Fig. 1B,C).
Western blot experiments showed a transient upregula-
tion of SDC4 expression during the proliferation
phase, and simultaneous a low level of mature myo-
statin and high level of promyostatin. The expression
of SDC4 markedly increased on day 1, but gradually
decreased to the level of the untreated control sample
by day 14. During the proliferation phase we observed
little or no mature myostatin, and during the differen-
tiation phase the expression increased (Fig. 1B,C). In
contrast, the expression of precursor promyostatin
changed inversely with that of myostatin, indicating
the enhanced proteolytic cleavage of promyostatin dur-
ing the regeneration. By day 14 the expression levels
of promyostatin and SDC4 were similar to those in
untreated muscle (Fig. 1B,C). The regeneration process
was monitored by the expression of the muscle regula-
tory factor MyoD (Fig. 1B,C).
An excellent in vitro model exists to study muscle dif-
ferentiation, since shifting mouse C2C12 myoblasts from
growth medium to low-serum fusion medium induces the
formation of multinucleated, myosin expressing myo-
tubes [31]. We transferred proliferating C2C12 cells to
differentiation medium, and monitored the expression
pattern of SDC4. Western blot analysis showed
increased SDC4 expression in proliferating myoblasts,
and the level of SDC4 decreased during the differentia-
tion (Fig. 1D), similar to what was seen in the in vivo
model. Representative phase contrast images show myo-
tube formation during the differentiation (Fig. 1E).
SDC4 interacts with promyostatin in a heparan
sulfate-dependent manner
Since proteoglycans can bind and serve as a reservoir
for numerous growth factors this raised the question
whether SDC4 can bind myostatin. We performed co-
immunoprecipitation (co-IP) assays in un-injured (con-
trol, day 0) and injured (3 days after notexin injury)
m. soleus samples to monitor the potential interaction.
Anti-myostatin antibody co-immunoprecipitated SDC4
(Fig. 2A), and SDC4 co-immunoprecipitated with
promyostatin (Fig. 2B) in both un-injured and injured
soleus muscle samples. SDC4 mainly interacted with
promyostatin, the mature myostatin was not detectable
in the immunocomplex. Importantly, heparinase II
treatment following SDC4 co-IP abolished the interac-
tion of SDC4 with promyostatin (Fig. 2C) indicating
the role of heparan-sulfate chains in the interaction.
Both promyostatin and mature myostatin were detected
in the supernatant (digestion buffer) collected after hep-
arinase digestion of the immunocomplex (Fig. 2C).
SDC4 knockdown influences the levels of
heparane sulfate proteoglycans and myostatin
We performed qPCR assays to monitor the gene
expression of SDC family members and other heparan
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sulfate proteoglycans in C2C12 myoblast cells. C2C12
cells express all members of the SDC family; SDC4 is
the most abundant, and glypican-1 and perlecan are
also present (Fig. 3A). Silencing of SDC4 upregulated
the levels of SDC3 and SDC1, and slightly increased
the amount of SDC2 transcripts (Fig. 3B). The hep-
aran sulfate proteoglycan glypican-1 and perlecan
showed weak upregulation following SDC4 silencing.
Furthermore, the transcript levels of the myostatin
gene were also measured. The level of myostatin
mRNA increased in SDC4 knockdown cells, which
was significant in shSDC4#1 cell line (Fig. 3B).
We have found that SDC4 interacts with promyo-
statin; therefore, we tested the levels of promyostatin
and myostatin proteins in nontransfected C2C12 cells
and in cell lines stably transfected with plasmids
Fig. 1. Expression of SDC4 and myostatin during skeletal muscle regeneration. (A) Representative haematoxylin and eosin-stained sections
of control and regenerating soleus muscle of the rat on different days after notexin injection. Bar: 50 lm. (B) Aliquots of extracts containing
equivalent amounts of protein obtained from m. soleus on different days after notexin induced injury were subjected to SDS/PAGE, and
immunoblotted with anti-SDC4, anti-myostatin (AB3239-I), anti-MyoD and anti-GAPDH antibodies. Representative immunoblots are shown.
GAPDH level is decreased after the injury in the necrotic muscle. Representative Ponceau staining of the membrane is presented. (C)
Quantification of results, data are reported as means  SEM (n = 4 independent experiments at each time point). (D) Expression of SDC4
during the differentiation of C2C12 myoblasts (0–5 days). GAPDH shows the equal loading of the samples. (E) Representative images of
proliferating and differentiating (day 4) C2C12 cells. Arrowheads show the formation of myotubes. Bar: 200 lm.
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expressing shRNA against SDC4 (shSDC4#1,
shSDC4#2) or scrambled shRNA. We found that
SDC4 silencing increased the level of mature myostatin
of the cells, and decreased the amount of precursor
promyostatin (Fig. 4A); furthermore, increased the
level of phospho-pSMAD2Ser465/467 (Fig. 4A,C) indi-
cating enhanced myostatin signalling. Importantly, we
observed a significantly increased myostatin content in
the cell culture medium of SDC4 silenced cells
(Fig. 4B,C) consistent with the increased myostatin
level of the cells.
Silencing of SDC4 decreases the proliferation
rate of C2C12 myoblasts by decreasing the
progression from G1- to S-phase of the cell cycle
SDC4 can bind growth factors, and here we showed
that it can bind promyostatin. Therefore, we tested the
effect of SDC4 knockdown on myoblast proliferation.
Decreased proliferation of SDC4 silenced cells was
observed compared to nontransfected cells and myo-
blasts expressing a scrambled sequence (Fig. 5A). The
proliferation rate of shSDC4#1-transfected cells was
lower than that of the shSDC4#2 line in accordance
with the lower SDC4 level of shSDC4#1 cells.
FACS analysis of the cell cycle revealed that SDC4
silencing inhibited myoblast proliferation through
decreasing the transition from G1- to S-phase of the
cell cycle: the frequency of cells in G1 phase signifi-
cantly increased, while the frequency of cells in S- and
G2/M phases significantly decreased following SDC4
silencing (Fig. 5B,C).
Next we analysed the expression of proteins regulat-
ing the G1/S transition. The levels of cyclin E and
cyclin D1 decreased, and the amount of p21 increased
in SDC4 knockdown cells (Fig. 5D) in accordance
with the observed G1/S inhibition.
Discussion
Skeletal muscle is a highly dynamic tissue that can
undergo successful regeneration upon injury. SDCs
have been reported to play crucial role in muscle
development, maintenance and regeneration. The role
of SDCs has been shown in muscle development in
turkey, mice and Drosophila [17,18,32–34]. SDC4 is
essential during skeletal muscle development and
regeneration, and SDC4/ mice are unable to regen-
erate damaged muscle [18]; however, the underlying
mechanisms are poorly understood. Here we have
shown that the expression of SDC4 transiently
increased during the early stages of notexin-induced
in vivo regeneration of soleus muscle, in harmony with
Fig. 2. Characterization of SDC4–promyostatin interaction. (A) Co-
immunoprecipitations (co-IPs) were carried out with rabbit antiserum
to the C-terminal part of myostatin (AB3239) in un-injured (control,
day 0, d0) and injured (3 days after notexin injury, d3) soleus muscle
homogenates. Different volumes (20 and 7 lL) of the eluted
immunocomplex were loaded in case of the injured sample. The
blots were reacted with antibodies to SDC4 raised in goat. Myostatin
co-immunoprecipitated SDC4 in both cases. Input lanes represent
the total homogenates; 10% of the total protein amount used in co-
IP was loaded. (B) Co-IP assays were performed with anti-SDC4
antibodies, and the blots were reacted with anti-myostatin antisera
(AB3239). The negative control was incubated only with the
secondary antibody. For the input lanes, 10% of the total protein
amount used in co-IP was loaded. The additional band at ~ 42 kDa in
d0 input can be a processing intermediate of promyostatin. (C)
Heparan sulfate chains were digested in injured samples (d3; sample
1 and 2) with heparinase II enzyme following immunoprecipitation
with goat anti-SDC4 antibody. Different amounts (25 and 5 lL) of the
eluted volume of the heparinase II digested immunoprecipitate of
sample 1 were loaded. We could not detect promyostatin in the
immunoprecipitate after heparinase digestion. For the input lanes,
7.5% of the total protein amount used in co-IPs were loaded. Note,
that both promyostatin and mature myostatin were detected in the
supernatant (digestion buffer) after heparinase digestion.
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Fig. 3. Gene expression of heparan sulfate proteoglycans in C2C12 cells, the effect of SDC4 silencing. (A) qRT-PCR experiments were
performed to analyse the transcript levels of heparan sulfate proteoglycans (SDC1, SDC2, SDC3, SDC4, glypican-1 and perlecan) in C2C12
cells. Relative mRNA levels are shown, individual threshold cycle (Ct) values were normalized to the Ct values of HPRT. (B) Effect of SDC4
silencing on the transcript levels of heparan sulfate proteoglycans and myostatin. The log2 change values compared to empty vector-
transfected cells are shown. Data are reported as means  SEM (n = 3 independent experiments/each cell line). Data are reported as
means  SEM; *P < 0.05, ***P < 0.001, ****P < 0.0001.
Fig. 4. SDC4 influences the level of myostatin. (A) Representative western blot experiments show the levels of SDC4, promyostatin,
myostatin and phospho-pSMAD2Ser465/467 in nontransfected C2C12 myoblasts and in cell lines stably expressing shRNA against SDC4
(shSDC4#1, shSDC4#2) or scrambled shRNA. GAPDH shows the equal loading of the samples. (B) Cell culture media of the cells shown in
panel A were collected and subjected to SDS/PAGE, followed by immunoblotting with anti-myostatin antibody. (C) Quantification of the
results is reported as means  SEM (n = 3–5 independent experiments); *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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the earlier observed transient upregulation of SDC4
mRNA [5]. SDC4 is expressed ubiquitously; therefore,
it may have originated not only from muscle but from
other cell types (e.g. macrophages) on the day 1 of
regeneration. However, during in vitro myoblast differ-
entiation we found the same expression pattern: SDC4
was highly expressed in proliferating C2C12 myoblast
cells, and showed weak expression in differentiated
C2C12 myotubes.
Numerous heparan sulfate proteoglycans are
expressed in skeletal muscle tissue, including SDCs,
glycophosphatidyl-linked glypicans, extracellular
matrix perlecan, agrin or biglycan [35,36]. Here we
showed that silencing of SDC4 resulted in the upregu-
lation of heparan sulfate proteoglycans in C2C12 myo-
blast (SDC1, SDC2, SDC3, glypican-1, perlecan).
Earlier studies described that heparan sulfate chains
are involved in myogenesis: inhibition of proteoglycan
sulfation by chlorate treatment of either C2C12 cells
[37] or intact myofibres [17] affected the proper pro-
gression of the myogenic program, and induced the
fusion of MM14 myoblasts [38]. Heparan sulfate pro-
teoglycans play important role in the regulation of the
skeletal muscle satellite cells. The SDCs are considered
as co-receptors for numerous growth factor receptors
[7]. SDC4 is required for FGF and HGF signalling,
Fig. 5. SDC4 knockdown reduces the proliferation rate of C2C12 myoblasts by decreasing the progression from G1- to S-phase of the cell
cycle. (A) Proliferation of the nontransfected C2C12 cells, and cell lines stably transfected with vectors expressing shRNA against SDC4 or
scrambled shRNA was monitored by CellTiter-Glo assay for 36 h (n = 3 independent experiments/cell line at each time point). (B)
Quantification of the frequency of the cells in G1, S or G2/M phases of the cell cycle. Data are reported as means  SEM, n = 8–15
independent experiments/cell line; 20 000 cells/cell line were counted in each experiment; *P < 0.05, **P < 0.01, ****P < 0.0001. (C)
Representative images of the cell cycle analysis of scrambled and shSDC4#1 cells with the fitted curve in pink and respective cell cycle
phase terms in green (G1), yellow (S) and blue (G2/M). (D) Representative western blot images show the expression levels of p21, cyclin E
and cyclin D1 proteins in the different cell lines. Quantifications of results are shown (n = 4–10 independent experiments). Data are reported
as means  SEM; **P < 0.01, ***P < 0.001, ****P < 0.0001.
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and for satellite cell activation [18]; SDC3 attenuates
FGF and HGF signalling [18], and glypican-1
enhances differentiation by sequestration of FGF2
[39]. Loss of SDC3 in satellite cells prevents self-
renewal and rehoming of satellite cells to their niche,
maintaining a pool of activated, proliferating cells that
largely ameliorate muscular dystrophy in mdx mice
[40]. It has been shown that the binding of FGF2 to
its receptor requires prior binding to heparan sulfate
[15], and heparan sulfate is required for BMP-7 sig-
nalling [41].
The propeptides (prodomains) of the TGF-beta
superfamily members were shown to target their
growth factors to extracellular matrix molecules, for
example the propeptide of BMP-5 interacts with fib-
rillin-1 and fibrillin-2, and the propeptide of myostatin
interacts with the glycosaminoglycan (heparan sulfate)
chains of perlecan [42]. The authors discuss that the
TGF-beta-like growth factors are targeted to the extra-
cellular matrix (ECM) through specific interactions
between propeptides and ECM structural macro-
molecules [42]. Furthermore, perlecan is critical for
regulating myostatin signalling [43], and the proteogly-
can decorin binds myostatin and influences myostatin
signalling [44,45]. Latent TGF-beta binding proteins
(LTBPs) regulate the extracellular availability of latent
TGF-beta. Myostatin forms an inactive complex with
LTBP4 leading to a decreased level of active myostatin
[46], and LTBP4 contains a heparin-binding domain
[47].
Several members of the TGF-beta superfamily and
their antagonists were shown to bind heparin and hep-
aran sulfates; however, there is no published observa-
tion of the binding of myostatin to heparin/heparan
sulfates [48]. Interestingly, a set of proteins inhibiting
myostatin function show affinity towards heparan sul-
fates: the myostatin propeptide [42], LTBP4 [47], or
follistatin [49] were described to bind heparane sul-
fates. Follistatin is an important myostatin antagonist
[21], and the myostatin/follistatin complex can bind to
heparin, enhancing myostatin cell surface binding [50].
In this study we found that SDC4, a marker of
satellite cells, interacts with the TGF-beta family mem-
ber myostatin in a heparan sulfate-dependent manner.
On the basis of the co-IP experiments, we cannot
prove a direct interaction of the heparan sulfate chains
with promyostatin, and we cannot exclude the role of
other proteins in SDC4-promyostatin interaction
(Fig. 6). Knocking down of SDC4 slightly increased
myostatin gene expression. Despite these changes in
the transcript level, the amount of promyostatin pro-
tein decreased and the level of mature myostatin
increased, indicating the enhanced processing of
promyostatin protein. Furthermore, SDC4 silencing
could also result in changes in promyostatin secretion
or protein stability, thus influencing its bioavailability.
During skeletal muscle regeneration the level of
promyostatin decreased and the level of mature myo-
statin increased concomitantly, indicating the enhanced
proteolytic processing of promyostatin. Interestingly,
the level of SDC4 changed in line with the amount of
promyostatin, and the high level of SDC4 was associ-
ated with low level of mature myostatin. According to
this expression pattern and the co-IP results we can
conclude that interaction of SDC4 with promyostatin
decreased the cleavage of the latter.
Heparan sulfates can protect the growth factors
from proteolytic cleavage [12]; therefore, it would be a
reasonable hypothesis from our present data that hep-
aran sulfate binding can similarly protect promyostatin
from proteolytic activation. Since heparan sulfate
chains exhibit promiscuity in binding their respective
ligands, we cannot exclude the role of other proteogly-
cans in promyostatin binding. Here we showed the
presence of the other SDC family members, glypican-1
and perlecan in C2C12 myoblasts; however, SDC4 was
the most abundant. It is known that proteolytic matu-
ration of promyostatin can occur extracellularly,
beyond the Golgi network [22]. We conclude that
SDC4 may participate in the maintenance of the extra-
cellular promyostatin pool via binding and sequester-
ing promyostatin, thus diminishing the formation of
the active, mature myostatin and thereby regulating its
local activity.
Heparinase II cleaves heparan sulfate chains to give
rise primarily to disaccharides that are unlikely to
form stable complexes with promyostatin, allowing its
cleavage. Importantly, the mature myostatin was also
detected in the digestion buffer collected after hepari-
nase digestion of the immunocomplex; therefore, the
intact heparan sulfate chains might have blocked the
proteolytic processing of the bound promyostatin, and
the heparinase treatment released promyostatin and
made it accessible to proteolytic cleavage. The nega-
tively charged heparan sulfate chains show affinity
towards electropositive ligands; and the surface-
exposed basic residues of the proteins can provide the
binding site for heparan sulfates. This interaction
involves the binding of the negatively charged GAG to
the amino acid residues lysine and arginine, and can
also include protonated histidine residues at low pH
values [51]. The myostatin itself displays a polar sur-
face potential, with the bottom side facing the cell sur-
face on receptor binding being very electronegative
and the top very electropositive [50]. Interestingly, a
unique continuous electropositive surface is created
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when myostatin binds the follistatin isoform Fst288,
which significantly increases the affinity of follistatin for
heparin [50]. The mature myostatin domain probably is
involved in the binding process to SDC4 given the nat-
ure of its electropositive surface, but there is no evidence
from our present set of data that the carboxyl terminal
mature myostatin is involved in binding to SDC4.
Myostatin was shown to decrease myoblast prolifer-
ation by increasing p21 levels [28]. In accordance with
this result, here we found that SDC4 knockdown
increased the amount of myostatin and p21, and
decreased the proliferation of the cells. During muscle
differentiation the myogenin positive cells remain cap-
able of replicating DNA [52]; therefore, the upregula-
tion of p21 will be required to block the cell cycle,
which can be the consequence – at least partially – of
the increased myostatin signalling.
The inhibition of myostatin signalling by anti-myos-
tatin antibodies or activin receptor inhibitors seems to
be a great challenge to increase muscle mass in case of
muscle wasting diseases, for example cancer-associated
cachexia, age-related sarcopenia or plaster cast immobi-
lization [53]. The characterization of signalling path-
ways playing a role in myoblast proliferation and
differentiation is necessary to find new perspectives to
improve muscle regeneration following sport injuries, in
the case of aging, or muscle dystrophies. Our working
model shows that the presence of SDC4 can enhance
myoblast proliferation by increasing the effect of prolif-
erative factors (e.g. FGF2, HGF), and by simultane-
ously decreasing anti-proliferative myostatin signalling
(Fig. 6). SDC4 interacts with promyostatin in a heparan
sulfate-dependent manner and influences the level of
mature myostatin. Our results suggest that SDC4 may
regulate the local bioavailability of mature myostatin by
serving as a reservoir for promyostatin, subsequently
inhibiting the formation of active myostatin. Heparan
sulfate chains on other proteoglycans are also contribut-
ing to the regulation of myostatin but as SDC4 is more
highly expressed that the others; therefore, its contribu-
tion is likely to be of most importance. Our results can
help in better understanding the essential role of SDC4
during skeletal muscle development and regeneration.
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